The Company: Biotech is a pharmaceutical company based in Vancouver, Canada.˙FFFFA0 Biotech controls and is bringing to market a breakthrough diabetes drug.˙FFFFA0 The drug, called DIAB II, is classed as an insulin-sensitizing drug. Drugs of this type improve the body˙FFFF92s ability

to make use of insulin, the hormone that controls blood sugar levels.˙FFFFA0 Currently available insulin-sensitizers such as Avandia and Actos have huge sales volumes˙FFFFA0 -- over $700 million annually in the case of Avandia, and over $1 Billion for Actos˙FFFFA0 -- despite a number of drawbacks including potential liver toxicity.˙FFFFA0 The success of these drugs demonstrates the tremendous potential for an effective and safe insulin sensitizer such as DIAB II.

The Potential Market: The market for Type II Diabetes drug worldwide is estimated to be more than $10 billion annually.

Biotech˙FFFF92s first goal is to bring DIAB II onto the market in Latin America, as preparation for bringing DIAB II to the drug market in the U.S. and Canada. Discussions with potential pharmaceutical partners for the U.S. market have begun.

In Latin America, Mexico is first on the company˙FFFF92s list of target markets. In his report to shareholders issued March 1, 2002, the President of Biotech Holdings, Robert Rieveley, said: We believe that we are well positioned for receiving regulatory approval shortly.˙FFFFA0 Accordingly, we have been making preparations for supply of DIAB II to the Mexican market, which is the eighth largest pharmaceutical market in the world.

In Latin America, DIAB II has already been approved in Peru and Biotech has signed distribution agreements for Venezuela, Chile and Argentina.˙FFFFA0 In other markets, a distributor has been signed for Turkey and preliminary agreements are in place for Spain, Greece, South Africa and several markets in the Middle East and South Asia.

The U.S. patents that protect DIAB II - - issued on November 28, 2000 and September 18, 2001 - - confer the sole right to the use of treatments combining insulin-sensitizing drugs with any other standard medications for Type II Diabetes.˙FFFFA0 Many large pharmaceutical companies active in the diabetes field may be affected

In addition to its prescription drug business, Biotech has a non-prescription, personal care products division which is showing steady growth.˙FFFFA0 In addition to its growing private label business, this division is planning to launch a new line of high-margin cosmetic products, which will be sold primarily in the U.S.

Biotech˙FFFF92s revenues are set to grow sharply as markets for DIAB II open up, as non-prescription revenues grow and as the implications of the above-mentioned patents are pursued, with potential for royalty payments from major pharmaceutical companies. In his Report to Shareholders, the President of Biotech concluded: We look forward with enthusiasm to developments in the coming months.

There has been growing investor interest and substantial volumes in trading of BIOHF shares.˙FFFFA0 Since January 2002 trading has averaged nearly 1 million shares per week.˙FFFFA0 This suggests to some market watchers that a strong base is being formed, with the next step being a significant upward movement.˙FFFFA0˙FFFFA0 Research the growth potential of this special situation while the Company that developed, controls and markets DIAB II is still trading as a penny stock.

˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0